Published in Pharmacoeconomics on January 01, 2009
Treatment variation in stent choice in patients with stable or unstable coronary artery disease. Neth Heart J (2016) 1.02
Use of drug-eluting stents versus bare-metal stents in Korea: a cost-minimization analysis using population data. J Prev Med Public Health (2013) 0.77
Using meta-regression analyses in addition to conventional systematic review methods to examine the variation in cost-effectiveness results - a case study. BMC Health Serv Res (2016) 0.75
Predictive value of BMD for hip and other fractures. J Bone Miner Res (2005) 6.46
Assessment of fracture risk. Osteoporos Int (2004) 5.15
International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res (2002) 3.14
Alcohol intake as a risk factor for fracture. Osteoporos Int (2004) 2.34
Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int (2003) 1.76
Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess Health Care (2011) 1.71
Pitfalls in health-economic evaluations: the case of cost-effectiveness of prophylactic implantable cardioverter-defibrillator therapy in Belgium. Europace (2009) 1.42
A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporos Int (2004) 1.39
Adult obesity and the burden of disability throughout life. Obes Res (2004) 1.24
Adult obesity and number of years lived with and without cardiovascular disease. Obesity (Silver Spring) (2006) 1.17
Physical activity and life expectancy with and without diabetes: life table analysis of the Framingham Heart Study. Diabetes Care (2006) 1.11
Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int (2004) 1.09
A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population. BMJ Open (2012) 1.08
Questionable levels of evidence in new atrial fibrillation guidelines? Europace (2012) 1.05
Was the LIFE trial independent? Lancet (2002) 0.98
Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care (2009) 0.90
Primary prevention of cardiovascular disease: cost-effectiveness comparison. Int J Technol Assess Health Care (2007) 0.89
Cost-effectiveness of cardiac resynchronisation therapy for patients with moderate-to-severe heart failure: a lifetime Markov model. BMJ Open (2011) 0.84
Analysis of the costs of dialysis and the effects of an incentive mechanism for low-cost dialysis modalities. Health Policy (2013) 0.84
Cost-effectiveness of transcatheter aortic valve replacement: overoptimistic study results and a call for publication of complete trial results. Heart (2012) 0.84
Cost effectiveness of implantable cardioverter-defibrillators for primary prevention in a Belgian context. Appl Health Econ Health Policy (2008) 0.83
Multidisciplinary outpatient rehabilitation following cardiac revascularization or valve surgery: patient-related factors for uptake. Eur J Prev Cardiol (2012) 0.83
The cost-utility of catheter ablation of atrial fibrillation: a systematic review and critical appraisal of economic evaluations. BMC Cardiovasc Disord (2013) 0.82
Economic analysis of the use of drug-eluting stents from the perspective of Belgian health care. Acta Cardiol (2007) 0.81
Cost-effectiveness analyses of drug eluting stents versus bare metal stents: a systematic review of the literature. Health Policy (2009) 0.80
The importance of the comparator in economic evaluations: working on the efficiency frontier. Pharmacoeconomics (2011) 0.79
Legal and organizational aspects of remote cardiac monitoring: the example of implantable cardioverter defibrillators. Europace (2012) 0.79
Market introduction of innovative high risk medical devices: towards a recast of the directive concerning medical devices. Eur J Health Law (2011) 0.78
Measuring quality of life for certain events versus pre-specified points in time. Pharmacoeconomics (2010) 0.78
Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium. Acta Cardiol (2009) 0.77
Stent thrombosis: antiplatelets alone won't do the job. BMJ (2007) 0.76
Recommendations or mere prose? Eur Heart J (2008) 0.75
Are thrombolytic drugs not evidence-based medications? Arch Intern Med (2008) 0.75
Health technology assessment on catheter ablation of atrial fibrillation in Belgium. Europace (2013) 0.75
What is the evidence in favor of percutaneous aortic valve insertion? Am J Cardiol (2009) 0.75
How many CIN2+ lesions can be avoided through HPV 16/18 vaccination? Acta Obstet Gynecol Scand (2009) 0.75
The use of instrumental variables: an alternative to traditional modeling? Value Health (2011) 0.75
TAVI: reveal the truth, the whole truth, and nothing but the truth. J Med Econ (2013) 0.75
Percutaneous pulmonary and aortic valve insertion in Belgium: going for conditional reimbursement or waiting for further evidence? Int J Technol Assess Health Care (2009) 0.75
Calculating an intervention's (cost-)effectiveness for the real-world target population: the potential of combining strengths of both RCTs and observational data. Health Policy (2012) 0.75